Top-line data is around the corner and it may fuel big moves for this eye care stock.
Eye diseases continue to be a big problem in American healthcare and this emerging NASDAQ company has a solution for a common one.
Wall Street may soon have its eye on this growing player in the eye disease market, as it is developing first-in-class pharmaceutical therapies to treat inflammatory eye diseases. The company's immediate goal is the development of a first-in-class drug that combines both anti-inflammatory and ocular pain-reducing activity to treat dry eye disease (DED). Worldwide, 360 million patients suffer from DED. In the United States, 20 million patients suffer from this condition, with DED remaining a major unmet medical need.
This company's game-changing drug candidate is being developed to treat DED, a condition that is a significant unmet need in a multi-billion-dollar market. Now may be a critical time to have the company on your radar as not long ago, the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) to initiate a Phase 2, first-in-human, clinical study of their drug candidate for the treatment of DED! Should the company be successful with the results from the clinical trial in Q4 2023, the company could be in a strong negotiating position to clinch a business development partnership or trade sale to Big Pharma. Q4 is around the corner!
This message is a PAID ADVERTISEMENT for Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) from Interactive Offers. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $1,900. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO) on Smallcaps Daily website for additional information about the relationship between Interactive Offers and Okyo Pharma Limited (NASDAQ: OKYO) (LSE: OKYO).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
Post a Comment
Post a Comment